Advertisement

Pharmacological Prevention of Arrhythmic Recurrences

  • G. Chiaranda
  • M.L. Cavarra
  • C.L. Romeo
  • M. Chiaranda
  • T. Regolo
Conference paper

Keywords

Atrial Fibrillation Sinus Rhythm Chronic Atrial Fibrillation Maintain Sinus Rhythm Arrhythmic Recurrence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fuster V, Gibbons RJ (2001) ACC AHA/ESC: Guidelines for the management of patients with atrial fibrillation. Eur Heart J 22:1852–1923PubMedCrossRefGoogle Scholar
  2. 2.
    Boriani G, Biffi M, Branzi A (1998) Pharmacological treatment of atrial fibrillation: a review of prevention of recurrences and control of ventricular response. Arch Gerontol Geriatr 27:127–139CrossRefGoogle Scholar
  3. 3.
    Alessie MA (1998) Atrial electrophysiologic remodeling: another vicious circle. J Cardiovasc Elettrophysiol 9:1378–1393Google Scholar
  4. 4.
    Verhorst PMJ, Kamp O, Welling RC (2001) Transesophageal echocardiographic predictors for maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation. Am J Cardiol 79:1235–1239Google Scholar
  5. 5.
    Mattioli AV, Vivoli D, Bastia E (1997) Doppler echocardiographic parameters predictive of recurrence of atrial fibrillation of different etiologic origins. J Ultrasound Med 16:695–698PubMedGoogle Scholar
  6. 6.
    Deedwania PC, Singh BN, Ellenbogen K et al (1998) Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observation from the Veterans Affairs Congestive Heart Failure Survival Trial of Anti-arrhythmic Therapy (CHF-STAT). Circulation 98:2574–2579PubMedGoogle Scholar
  7. 7.
    Anderson JL, Gilbert EM, Alpbert PL et al (1989) Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating anti-arrhythmic therapy. A multicenter double-blind crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 80:1557–1570PubMedGoogle Scholar
  8. 8.
    Pietersen H, Hellemann H (1991) Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol 67:713–717PubMedCrossRefGoogle Scholar
  9. 9.
    Carelli G, Dorian P (1996) Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 77:53A–59ACrossRefGoogle Scholar
  10. 10.
    Van Wijklm, Den Heijr P (1989) Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol 13:32–36Google Scholar
  11. 11.
    Van Gelder IC, Crijnshj (1989) Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 64:1317–1321PubMedCrossRefGoogle Scholar
  12. 12.
    Lee Sh, Chen S, Chiang CE et al (1996) Comparison of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med 239:253–260PubMedCrossRefGoogle Scholar
  13. 13.
    Reinol SC, Cantillon CO (1993) Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 79:1198–1202Google Scholar
  14. 14.
    Alboni P, Botto GL (2005) Out of hospital treatment of recent onset atrial fibrillation with the “pill in the pocket” approach. N Engl J Med (in press)Google Scholar
  15. 15.
    Kochiadakis GE, Igoumenidis NE, Marketou ME et al (2000) Low dose amiodarone and sotalol in the treatment of recurrent symptomatic atrial fibrillation: comparative placebo controlled study. Heart 84:251–257PubMedCrossRefGoogle Scholar
  16. 16.
    Roy D, Talajic M (2000) Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342:913–920PubMedCrossRefGoogle Scholar
  17. 17.
    Vitolo E, Tronci M, La Rovere M (1981) Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 36: 431–434PubMedGoogle Scholar
  18. 18.
    Vorperian VR, Havighurst TC (1997) Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 30:791–798PubMedCrossRefGoogle Scholar
  19. 19.
    Sing S, Zoble RG (2000) Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation 102:2385–2390Google Scholar
  20. 20.
    Greenbaum RA, Campbell TJ (1998) Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide: DE EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study. Circulation 98:1663–1671Google Scholar
  21. 21.
    Kuhlkamp V, Schirdewan A, (2000) Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. A randomized doubleblind placebo-controlled study. J Am Coll Cardiol 36:139–146PubMedCrossRefGoogle Scholar
  22. 22.
    Lucio E, Flores A (2003) Effectiveness of metoprolol in prevention of atrial fibrillation and flutter in the postoperative period of coronary artery by-pass graft surgery. Arq Bras Cardiol 82:42–46Google Scholar
  23. 23.
    Toboul P, Brugada, Capucci A (2003) Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 24:1481–1487CrossRefGoogle Scholar
  24. 24.
    Rossiem Lown B (1967) The use of quinidine in cardioversion. Am J Cardiol 19:234–238CrossRefGoogle Scholar
  25. 25.
    Cappucci A, Villani GQ, Aschieri D (2000) Oral amiodarone increases the efficacy of direct current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 21:66–73CrossRefGoogle Scholar
  26. 26.
    Botto GL, Belotti G, Ciro A, on behalf of the VERAF study group (2002) Verapamil in prevention of early recurrence of atrial fibrillation: final results of the VERAF study. Eur Heart J 23:660Google Scholar
  27. 27.
    De Simone A, De Pasquale M, De Matteis C, on behalf of the VEPARAF study (2003) Verapamil class antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). Eur Heart J 24: 1425–1429PubMedCrossRefGoogle Scholar
  28. 28.
    Madrid AH, Bueno MG (2002) Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation 106:16CrossRefGoogle Scholar
  29. 29.
    Chiaranda G, Cavarra ML, Busacca G (2004) The role of candesartan in the maintenance of sinus rhythm in patient with atrial fibrillation lasting > 48 h, Italian Heart J, 5(Suppl 5):C108Google Scholar

Copyright information

© Springer-Verlag Italia 2005

Authors and Affiliations

  • G. Chiaranda
    • 1
  • M.L. Cavarra
    • 1
  • C.L. Romeo
    • 1
  • M. Chiaranda
    • 1
  • T. Regolo
    • 2
  1. 1.Coronary Care UnitMuscatello HospitalAugusta (Syracuse)
  2. 2.Coronary Care UnitFerrarotto University HospitalCataniaItaly

Personalised recommendations